Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue

Demonstrates ongoing commitment to address the world's most pressing health care needs

- With a strong in-market portfolio and a robust near-term pipeline, the Pharmaceutical segment is well-positioned to drive continued above-industry compound annual growth through 2019

- Plans to file more than 10 new molecular entities and more than 40 line extensions by 2019 demonstrate industry-leading R&D productivity

- Beyond 2019, focused R&D strategy and investment are delivering a deep, innovative early-stage pipeline

May 20, 2015, 07:30 ET from Johnson & Johnson

NEW BRUNSWICK, N.J., May 20, 2015 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will announce plans to file for regulatory approval of more than 10 new products between 2015 and 2019, each with the potential to exceed $1 billion in revenue1, as well as more than 40 line extensions of existing and new medicines.

With a portfolio focused on five core therapeutic areas – Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology – the Pharmaceutical segment of Johnson & Johnson (NYSE: JNJ) is delivering transformational new medicines for unmet medical needs worldwide.  Janssen has launched 14 new products since 2009, seven of which already exceed or are on track to achieve sales in excess of $1 billion during 2015.2 These new products, coupled with core growth brands, have fueled industry-leading sales growth and contributed significantly to the earnings growth of Johnson & Johnson. The combined strength of Janssen's in-market portfolio and robust near-term pipeline provides the momentum to sustain above-industry compound annual growth through 2019.

"In the past two years, our performance and growth rates have been industry-leading, and we look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines," said Joaquin Duato, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "We are working with our partners to advance the innovative products in our pipeline and to deliver significant benefits to patients."

The total pharmaceutical market reached $1 trillion in 2014 with nearly 40 percent of the growth coming from specialty medicines, including oncology, autoimmune, respiratory and anti-viral medications. Going forward, the total global branded pharmaceuticals market is expected to grow at a compound annual operational growth rate of approximately 3 percent from 2014 to 2019, according to IMS Health, the independent analysis and market research service that tracks the industry. Among the top 10 global pharmaceutical companies, IMS Health also reports that the Pharmaceutical segment of Johnson & Johnson was among the fastest growing in the U.S., Europe and Japan in 2014, with sales of $32.3 billion, representing an operational increase of 16.5 percent3 versus 2013.

"Our innovation strategy has delivered transformational products for patients and also created a cycle of success that positions us for continued growth across the entire Johnson & Johnson enterprise," said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "With a single-minded focus on unmet medical need and true differentiation, we've built an industry-leading pipeline to improve and extend people's lives and also create value for society and our business."

Late-stage products expected to drive growth in the next several years, following regulatory approvals, include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer; esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C.4 In addition, daratumumab and esketamine have both received Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA). Janssen is also announcing today that it plans to submit a Biologic Licensing Application to the FDA and a Marketing Authorization Application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase 2 data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.

"Our innovation model and capital allocation framework provide us the flexibility to source both internal and external innovations to create an industry-leading portfolio that is advancing our vision of a world without disease," said Dominic J. Caruso, Vice President, Finance and Chief Financial Officer, Johnson & Johnson.

In February 2015, Janssen announced the launch of three new research platforms focused on disease prevention, disease interception, and the microbiome, to underpin ongoing research and propel scientific knowledge in these areas of significant potential to change the way diseases are managed. The Janssen Prevention Center focuses on prevention of chronic, non-communicable diseases; the Disease Interception Accelerator is focused on tackling the origins of disease and intercepting progression to disease for people at-risk – before they get sick; and the Janssen Human Microbiome Institute focuses on the diverse population of bacteria living in and on the human body to develop therapeutic targets and diagnostic capabilities that have the potential to transform human health.

"The future of health care lies in not only treating disease but also preventing and intercepting diseases before illness occurs," said William N. Hait, M.D., Ph.D., Global Head of Janssen Research & Development. "Using our powerful research platforms in combination with our five focused therapeutic areas, underpinned by strong in-house capabilities and cutting-edge external partnerships, we are striving to deliver the next generation of medical innovations that prevent, intercept and treat disease."

About Today's Meeting

The meeting will be webcast starting at 8:30 a.m. today and can be accessed along with full copies of the presentations and speaker biographies via the Johnson & Johnson Investor Relations website: www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast. A live Twitter feed for today's meeting is accessible via #JNJPharm15.

Users of the Johnson & Johnson Investor Relations mobile app for the iPad® and iPhone® mobile digital devices can also access the event. This free app is available in the iTunes® store and includes stock information, news releases, company information, webcasts, SEC filings, the company's pharmaceutical product pipeline and Annual Reports, among other information.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

 

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities regarding approval, labeling and other matters that could affect the availability or commercial potential of product candidates; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; challenges to patents; the impact of patent expirations; impact of business combinations and divestitures; competition, including technological advances, new products and patents attained by competitors; future clinical data and analysis, including post marketing surveillance; economic factors, such as interest rate and currency exchange rate fluctuations; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; product efficacy or safety concerns resulting in product recalls or regulatory action; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. The Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.

 

iPad, iPhone and iTunes are trademarks of Apple Inc.

1 Peak non-adjusted sales, including partner sales, where applicable.

2 Includes partner sales, where applicable.

3 Operational growth excludes the effect of translational currency; total reported growth was 14.9 percent.

4 Many of these products were developed in collaboration with strategic partners or are licensed from other companies; see webcast presentation for more information.

SOURCE Johnson & Johnson



RELATED LINKS

http://www.jnj.com